Momenta’s shift to innovative pipeline pays off with $6.5B J&J takeout

Momenta’s 2018 decision to reorganize its business around its innovative pipeline was the critical step that positioned the biotech for its $6.5 billion takeout by J&J, announced Wednesday.

The company had deprioritized its complex generics and biosimilars businesses nearly two years ago to focus on a pipeline whose lead asset, anti-FCRN mAb nipocalimab (M281), delivered proof-of-concept data in June from a Phase II study to treat the neuromuscular disease generalized myasthenia gravis (gMG)...